Takeda (NYSE: TAK) executive discloses 193,148 ADS and 85,802 RSUs
Rhea-AI Filing Summary
Takeda Pharmaceutical executive Teresa Marie Bitetti, President of the Oncology Business Unit, reports beneficial ownership of 193,148 American Depositary Shares. This total includes 85,802 restricted stock units, each convertible into one ADS.
The RSUs are scheduled to vest in three tranches: 40,056 shares on July 1, 2026, 30,564 shares on July 1, 2027, and 15,182 shares on July 1, 2028, providing a clearly defined equity vesting timeline.
Positive
- None.
Negative
- None.
Insider Trade Summary
1 transaction reported
Mixed
1 txn
Insider
Bitetti Teresa Marie
Role
President, OBU
| Type | Security | Shares | Price | Value |
|---|---|---|---|---|
| holding | American Depositary Shares | -- | -- | -- |
Holdings After Transaction:
American Depositary Shares — 193,148 shares (Direct)
Footnotes (1)
- F1. Includes 85,802 restricted stock units (RSUs). Each RSU represents a contingent right to receive one American Depositary Share. The RSUs vest on the following schedule: July 1, 2026 (40,056 shares), July 1, 2027 (30,564 shares) and July 1, 2028 (15,182 shares).
AI-generated analysis. How Rhea-AI works. Not financial advice.
FAQ
What insider position does Teresa Marie Bitetti hold at Takeda (TAK)?
Teresa Marie Bitetti is identified as an officer of Takeda, serving as President of the Oncology Business Unit (OBU). This role ties her equity holdings and restricted stock units directly to the company’s oncology-focused operations and long-term performance incentives.
How many restricted stock units are included in Teresa Bitetti’s Takeda (TAK) holdings?
Her reported position includes 85,802 restricted stock units (RSUs). Each RSU represents a contingent right to receive one Takeda American Depositary Share, aligning a substantial portion of her compensation with the company’s future share performance over a defined vesting schedule.
What is the vesting schedule for Teresa Bitetti’s Takeda (TAK) RSUs?
The RSUs vest in three installments: 40,056 shares on July 1, 2026, 30,564 shares on July 1, 2027, and 15,182 shares on July 1, 2028. This staggered schedule supports ongoing retention and long-term performance alignment.